SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

10 Nov 2021 Evaluate
The revenue for the September 2021 quarter is pegged at Rs. 1688.53 millions, about 22.76% up against Rs. 1375.52 millions recorded during the year-ago period.A humble growth in net profit of 17.26% reported in the quarter ended September 2021 to Rs. 275.97  millions from Rs. 235.34 millions.The company reported a good operating profit of 425.27 millions compared to 360.04 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 1688.53 1375.52 22.76 3160.74 2935.11 7.69 5995.48 4334.15 38.33
Other Income 85.98 129.57 -33.64 225.38 130.06 73.29 311.56 1.73 17909.25
PBIDT 425.27 360.04 18.12 815.64 650.56 25.38 1448.68 716.63 102.15
Interest 12.02 13.21 -9.01 18.32 21.09 -13.13 53.45 72.92 -26.70
PBDT 413.25 346.83 19.15 797.32 629.47 26.67 1395.23 643.71 116.75
Depreciation 43.04 36.71 17.24 85.33 70.14 21.66 151.93 116.44 30.48
PBT 370.21 310.12 19.38 711.99 559.33 27.29 1243.30 527.27 135.80
TAX 94.24 74.78 26.02 146.96 103.43 42.09 259.49 148.24 75.05
Deferred Tax 18.60 11.20 66.07 15.08 -22.87 -165.94 -22.39 36.77 -160.89
PAT 275.97 235.34 17.26 565.03 455.90 23.94 983.81 379.03 159.56
Equity 409.31 409.31 0.00 409.31 409.31 0.00 409.31 409.31 0.00
PBIDTM(%) 25.19 26.17 -3.78 25.81 22.16 16.42 24.16 16.53 46.14

Marksans Pharma Share Price

178.95 -0.60 (-0.33%)
20-Apr-2026 09:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.00
Dr. Reddys Lab 1233.90
Cipla 1241.30
Zydus Lifesciences 947.00
Lupin 2328.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×